All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Looking at Trends in Parenteral Manufacturing

June 21, 2017
By Jennifer Markarian
News
Article

Equipment and Processing Report

Equipment and Processing ReportEquipment and Processing Report-06-21-2017
Volume 10
Issue 7

The need for flexibility and higher quality are driving advances in parenteral manufacturing and fill/finish equipment.

As part of Pharmaceutical Technology’s 40th Anniversary issue, which will be published in July, the editors interviewed industry experts about the biggest changes the industry has seen in the past 40 years and what they foresee for the future. The trend toward specialized medicines focused on smaller patient populations is leading to smaller production batches and a greater need for flexibility in manufacturing equipment and systems, says Bernd Stauss, senior vice-president of Pharmaceutical Production/Engineering at Vetter Pharma-Fertigung. The increase in highly potent drugs is another driver for equipment advances, notes Christian Treitel, director, Business Development Pharma, Bosch Packaging Technology. Pharmaceutical Technology spoke with Stauss and Treitel about developments in parenteral manufacturing and fill/finish.

PharmTech: What have been the most significant changes in parenteral pharmaceutical manufacturing and fill/finish in the past 40 years?

Treitel (Bosch): In the past 40 years, we have seen significant increases in automation and the use of barrier systems like restricted access barrier systems (RABS), closed RABS, and isolators. More complex processes can be managed, product quality has improved, and operating costs have been reduced. A wider variety of packaging styles-ready-to-fill syringes and, recently, vials and cartridges-and flexible machine platforms offer pharmaceutical manufacturers the flexibility for different products and requirements. Pharmaceutical manufacturers also more often require 100% in-process checkweighing to prevent product loss of expensive drugs.

Stauss (Vetter): The primary development in parenteral pharmaceutical manufacturing we have experienced over the past 40 years has been the continuous improvement in the quality of the drug manufacturing process. This has had an impact on the entire bio/pharmaceutical industry supply chain. Over this time period, automation grew rapidly and continues to do so today. At Vetter, for example, the use of robots in the production process had already begun by the 1990s.

From a technological aspect, single-use technology is an emerging trend in the fill-and-finish segment, primarily in the early phases of a drug-development project. A large part of the industry, however, does not believe that single-use equipment will replace stainless-steel technology as a whole. Nevertheless, single-use technology offers a valuable option within special fields of the production process. In our experience, both technologies have their individual pros and cons.

Today, we see two specific leading cleanroom technologies on the market: RABS technology and isolators. RABS achieves the sterility assurance level (SAL) required by regulatory authorities and allows for rapid product changeover along with high safety. To better meet future industry trends in quality, safety, and flexibility, combining the advantages of both isolator and RABS technology appears to have promising potential for a contract development and manufacturing organization like Vetter. An improved RABS concept, called Vetter CleanRoom Technology (V-CRT), achieves fast and fully-automated decontamination of the cleanroom using hydrogen peroxide.

PharmTech: What trends or new developments do you foresee for the near future?

Stauss (Vetter): One of the primary developments we see is the increase in the overall complexity of individual drug substances which, in turn, affects all parties along the supply chain that are involved in the handling and processing of these substances. Expectations for quality are high, with customers demanding a significant level of oversight.

Patients are asking for innovative drug-delivery systems that fit better with the ‘mobile lifestyle’ of today. Having access to those systems supports their individual acceptance and compliance. Large areas of the developed world are experiencing growth in aged populations, which has resulted in an increase of associated diseases. As they can often be treated in private settings, there has been an impact on the homecare sector, thus creating a need for appropriate devices, such as pens and autoinjectors. Finally, we have experienced an increase in topics such as digitalization.

Treitel (Bosch): In order to further reduce or avoid human interventions, there will be fully automated production lines with the use of robotics. Connected industry solutions will bring more intelligence into production. These technologies will help achieve higher productivity, safety, and efficiency.

Articles in this issue

Looking at Trends in Parenteral Manufacturing
PT0517_Marchesini_fig1_300-New-1497385166986.jpg
Robots Package Parenteral Products
Countering the Loss in Efficiency Caused by Mandated Serialization Compliance
EPR0617_Leistritzseminar_Rollers_300.jpg
Twin-Screw Extruders Serve the Pharma Industry
Recent Videos
Drug Digest: Patient Preference Drives Solid Dosage Trends
Behind the Headlines, Episode 17
Related Content

Gold winners award with three stars | Image Credit: © sergign - stock.adobe.com

ISPE Announces Six 2025 FOYA Category Winners

Patrick Lavery
May 15th 2025
Article

Six winners and two honorable mentions were revealed at ISPE’s Europe Annual Conference in London.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Piramal Pharma to Invest $90 Million at Kentucky & Michigan Sites

Patrick Lavery
May 12th 2025
Article

The company said the investment is in response not only to customer demand and a belief in the value of US-based innovation, but also because of the trend toward US onshoring brought about by new tariff policies.


Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.


Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

New CBER Director Appointed

Susan Haigney
May 7th 2025
Article

FDA chooses Dr. Vinay Prasad, MD, MPH, a hematologist-oncologist, to lead the Center for Biologics Evaluation and Research at FDA.


Image Credit: © Alessandro Grandini - stock.adobe.com

Understanding the Variability in Bioburden Test Results in Biomanufacturing

Naveenganesh Muralidharan
May 7th 2025
Article

This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.

Related Content

Gold winners award with three stars | Image Credit: © sergign - stock.adobe.com

ISPE Announces Six 2025 FOYA Category Winners

Patrick Lavery
May 15th 2025
Article

Six winners and two honorable mentions were revealed at ISPE’s Europe Annual Conference in London.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Piramal Pharma to Invest $90 Million at Kentucky & Michigan Sites

Patrick Lavery
May 12th 2025
Article

The company said the investment is in response not only to customer demand and a belief in the value of US-based innovation, but also because of the trend toward US onshoring brought about by new tariff policies.


Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.


Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

New CBER Director Appointed

Susan Haigney
May 7th 2025
Article

FDA chooses Dr. Vinay Prasad, MD, MPH, a hematologist-oncologist, to lead the Center for Biologics Evaluation and Research at FDA.


Image Credit: © Alessandro Grandini - stock.adobe.com

Understanding the Variability in Bioburden Test Results in Biomanufacturing

Naveenganesh Muralidharan
May 7th 2025
Article

This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.